NRAS and mucosal melanoma: on anti‐PD‐1 antibody plus axitinib as first‐line treatment in advanced mucosal melanoma reported an ORR of 62.5% (5/8) among those with NRAS mutations, which is twice as high as that of the entire cohort (30.0%, 24/80).37